Equity Overview
Price & Market Data
Price: $5.61
Daily Change: -$0.79 / 14.08%
Range: $5.60 - $6.88
Market Cap: $106,740,352
Volume: 19,943
Performance Metrics
1 Week: -24.39%
1 Month: -24.09%
3 Months: -71.64%
6 Months: -71.64%
1 Year: -71.64%
YTD: -53.67%
Company Details
Employees: 4
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is based in Calabasas, California.